Teva Will Assume Azilect Marketing From Eisai
This article was originally published in The Pink Sheet Daily
Teva will assume full U.S. marketing responsibilities for Azilect (rasagiline) for Parkinson's disease following dissolution of its co-development agreement with Eisai, the companies announced July 12
You may also be interested in...
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.